Peter W Hunt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4584067/publications.pdf

Version: 2024-02-01

296 papers 23,115 citations

74 h-index

9264

9861

307 all docs

307 docs citations

307 times ranked

20286 citing authors

g-index

#	Article	IF	CITATIONS
1	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 74, 95-104.	5.8	31
2	Association of elevated plasma inflammatory biomarker levels with age-related macular degeneration but not cataract in persons with AIDS. Aids, 2022, 36, 177-184.	2.2	4
3	Objective Identification of Cannabis Use Levels in Clinical Populations Is Critical for Detecting Pharmacological Outcomes. Cannabis and Cannabinoid Research, 2022, 7, 852-864.	2.9	4
4	IFN- $\hat{l}\pm$ blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight, 2022, 7, .	5.0	6
5	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+T cells. Journal of Clinical Investigation, 2022, 132, .	8.2	52
6	Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 369-376.	2.1	24
7	Plasma CD16 ⁺ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV ⁺ Adults on Combination Antiretroviral Therapy. MBio, 2022, 13, e0300521.	4.1	6
8	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Reports, 2022, 39, 110815.	6.4	0
9	Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine, 2022, 80, 104072.	6.1	9
10	Multiple substance use, inflammation and cardiac stretch in women living with HIV. Drug and Alcohol Dependence, 2022, 238, 109564.	3.2	1
11	A hidden menace? Cytomegalovirus infection is associated with reduced cortical gray matter volume in major depressive disorder. Molecular Psychiatry, 2021, 26, 4234-4244.	7.9	19
12	Association Between Immunoglobulin E Levels and Kaposi Sarcoma in African Adults With Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2021, 223, 101-108.	4.0	4
13	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1621-1630.	4.0	20
14	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 1839-1848.	4.0	176
15	Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. Aids, 2021, 35, 1083-1089.	2.2	7
16	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight, 2021, 6, .	5.0	43
17	Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV. Aids, 2021, 35, 1031-1040.	2.2	15
18	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. Journal of Infectious Diseases, 2021, 224, 1593-1598.	4.0	14

#	Article	IF	Citations
19	Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection. Current Opinion in HIV and AIDS, 2021, 16, 168-176.	3.8	14
20	Alcohol Consumption and Tryptophan Metabolism Among People with HIV Prior to Antiretroviral Therapy Initiation: The Uganda ARCH Cohort Study. Alcohol and Alcoholism, 2021, , .	1.6	1
21	Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection. Open Forum Infectious Diseases, 2021, 8, ofab245.	0.9	6
22	Treated HIV Infection and Progression of Carotid Atherosclerosis in Rural Uganda: A Prospective Observational Cohort Study. Journal of the American Heart Association, 2021, 10, e019994.	3.7	11
23	Association between cytomegalovirus infection, reduced gray matter volume, and resting-state functional hypoconnectivity in major depressive disorder: a replication and extension. Translational Psychiatry, 2021, 11, 464.	4.8	11
24	HIV-1 Genomes Are Enriched in Memory CD4 ⁺ T-Cells with Short Half-Lives. MBio, 2021, 12, e0244721.	4.1	11
25	Replicable association between human cytomegalovirus infection and reduced white matter fractional anisotropy in major depressive disorder. Neuropsychopharmacology, 2021, 46, 928-938.	5.4	16
26	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	4.7	25
27	Internalized stigma, depressive symptoms, and the modifying role of antiretroviral therapy: A cohort study in rural Uganda. SSM Mental Health, 2021, 1, 100034.	1.8	5
28	Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States. American Journal of Epidemiology, 2020, 189, 554-563.	3.4	4
29	Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. Journal of Infectious Diseases, 2020, 221, 1146-1155.	4.0	11
30	Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. Aids, 2020, 34, 2013-2024.	2.2	14
31	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 ⁺ and Gut CD4 ⁺ T Cells. Journal of Virology, 2020, 95, .	3.4	4
32	Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. PLoS Pathogens, 2020, 16, e1008813.	4.7	20
33	Genetic architecture of cardiometabolic risks in people living with HIV. BMC Medicine, 2020, 18, 288.	5.5	11
34	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Journal of Virology, 2020, 94, .	3.4	6
35	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open, 2020, 10, e031487.	1.9	4
36	Super learner analysis of realâ€time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to nonâ€differentiated care approaches for persons living with HIV in rural Uganda. Journal of the International AIDS Society, 2020, 23, e25467.	3.0	12

#	Article	IF	CITATIONS
37	Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 1604-1610.	3.0	8
38	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 530-537.	2.1	17
39	HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nature Immunology, 2020, 21, 274-286.	14.5	60
40	Presence of asymptomatic cytomegalovirus and Epstein-Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. Aids, 2020, 34, 849-857.	2.2	27
41	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. Journal of Virology, 2020, 94, .	3.4	20
42	Differential decay of intact and defective proviral DNA in HIV-1 ${\hat a} \in {}^{\!\!\!\!\!\!\!\!\!\!^{\prime}}$ infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	5.0	140
43	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	3.1	42
44	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. ELife, 2020, 9, .	6.0	63
45	Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy. Clinical Infectious Diseases, 2019, 68, 1394-1401.	5.8	24
46	Association of Gut Intestinal Integrity and Inflammation with Insulin Resistance in Adults Living with HIV in Uganda. AIDS Patient Care and STDs, 2019, 33, 299-307.	2.5	5
47	Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post–Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight. Journal of Immunology, 2019, 203, 899-910.	0.8	11
48	Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS). BMC Medicine, 2019, 17, 149.	5.5	22
49	Pneumoproteins are associated with pulmonary function in HIV-infected persons. PLoS ONE, 2019, 14, e0223263.	2.5	8
50	Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction. Epidemiology, 2019, 30, 69-74.	2.7	12
51	Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?. Journal of Infectious Diseases, 2019, 220, 1867-1869.	4.0	10
52	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 89-93.	2.1	41
53	Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study. Journal of Infectious Diseases, 2019, 220, 1172-1177.	4.0	8
54	Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS., 2019, 60, 2218.		9

#	Article	IF	CITATIONS
55	HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia. PLoS ONE, 2019, 14, e0216680.	2.5	9
56	Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIVâ€Infected Adults. Journal of the American Heart Association, 2019, 8, e011037.	3.7	15
57	Increased mucosal neutrophil survival is associated with altered microbiota in HIV infection. PLoS Pathogens, 2019, 15, e1007672.	4.7	36
58	Participating in Human Immunodeficiency Virus Cure Research at the End of Life. Clinical Infectious Diseases, 2019, 69, 1068-1070.	5.8	12
59	Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e141-e147.	2.1	9
60	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 211-219.	2.1	14
61	High Incidence of Intended Partner Pregnancy Among Men Living With HIV in Rural Uganda: Implications for Safer Conception Services. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 497-507.	2.1	6
62	Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 386-391.	2.1	14
63	Changes in the Fungal Marker \hat{l}^2 -D-Glucan After Antiretroviral Therapy and Association With Adiposity. Open Forum Infectious Diseases, 2019, 6, ofz434.	0.9	15
64	Association of Age-related Macular Degeneration With Mortality in Patients With Acquired Immunodeficiency Syndrome; Role of Systemic Inflammation. American Journal of Ophthalmology, 2019, 199, 230-237.	3.3	8
65	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. AIDS and Behavior, 2019, 23, 627-635.	2.7	21
66	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. Journal of Virology, 2019, 93, .	3.4	17
67	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathogens and Immunity, 2019, 4, 147.	3.1	15
68	Inflammation Investigated as a Source of Pharmacokinetic Variability of Atazanavir in AIDS Clinical Trials Group Protocol A5224s. Antiviral Therapy, 2018, 23, 345-351.	1.0	6
69	Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy–Treated Human Immunodeficiency Virus–Infected Individuals. Clinical Infectious Diseases, 2018, 66, 1872-1882.	5.8	85
70	Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. Journal of Histochemistry and Cytochemistry, 2018, 66, 427-446.	2.5	19
71	Brief Report: Systemic Inflammation, Immune Activation, and Impaired Lung Function Among People Living With HIV in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 543-548.	2.1	18
72	Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. Aids, 2018, 32, 767-771.	2.2	36

#	Article	IF	CITATIONS
73	All About the Albumin? Prognostic Capacity of Serum Albumin in Patients With Treated HIV Infection. Journal of Infectious Diseases, 2018, 217, 347-349.	4.0	2
74	Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. Journal of Immunology, 2018, 200, 1876-1888.	0.8	28
75	Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 507-513.	2.1	30
76	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. Journal of Infectious Diseases, 2018, 218, 239-248.	4.0	29
77	Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?. Journal of Infectious Diseases, 2018, 217, 521-528.	4.0	18
78	Increased Systemic Inflammation and Gut Permeability Among Women With Treated HIV Infection in Rural Uganda. Journal of Infectious Diseases, 2018, 218, 922-926.	4.0	40
79	Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain, Behavior, and Immunity, 2018, 71, 108-115.	4.1	26
80	Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. Mucosal Immunology, 2018, 11, 909-920.	6.0	38
81	Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. PLoS Pathogens, 2018, 14, e1007357.	4.7	76
82	Contraceptive use following unintended pregnancy among Ugandan women living with HIV. PLoS ONE, 2018, 13, e0206325.	2.5	7
83	Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome. , 2018, 59, 904.		6
84	HIV DNA decay during antiretroviral therapy. Aids, 2018, 32, 2255-2257.	2.2	3
85	Prevalence and correlates of physical and sexual intimate partner violence among women living with HIV in Uganda. PLoS ONE, 2018, 13, e0202992.	2.5	26
86	Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda. Annals of Internal Medicine, 2018, 169, 146.	3.9	18
87	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Research and Human Retroviruses, 2018, 34, 916-921.	1.1	2
88	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005–2013. AIDS Patient Care and STDs, 2018, 32, 257-264.	2.5	13
89	<i>CYP2B6</i> Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Research and Human Retroviruses, 2018, 34, 982-992.	1.1	6
90	The Clinical-Translational Physician-Scientist: Translating Bedside to Bench. Journal of Infectious Diseases, 2018, 218, S12-S15.	4.0	5

#	Article	IF	CITATIONS
91	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Journal of Infectious Diseases, 2018, 218, 1394-1403.	4.0	36
92	Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 458-464.	2.1	15
93	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathogens, 2018, 14, e1006806.	4.7	12
94	Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression. Journal of Virology, 2017, 91, .	3.4	34
95	Incidence of Intermediate-stage Age-related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome. American Journal of Ophthalmology, 2017, 179, 151-158.	3.3	25
96	Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e132-e141.	2.1	5
97	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	4.0	95
98	Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 183-187.	2.1	14
99	Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes, 2017, 8, 440-450.	9.8	56
100	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	1.1	22
101	Types of Myocardial Infarction Among Human Immunodeficiency Virus–Infected Individuals in the United States. JAMA Cardiology, 2017, 2, 260.	6.1	61
102	An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. AIDS Research and Human Retroviruses, 2017, 33, S-31-S-39.	1.1	23
103	Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. Aids, 2017, 31, 2345-2354.	2.2	23
104	MicroRNAs. Aids, 2017, 31, 2017-2018.	2.2	0
105	Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. Aids, 2017, 31, 169-171.	2.2	31
106	Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 188-192.	2.1	1
107	Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. AIDS and Behavior, 2017, 21, 1735-1740.	2.7	17
108	Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. AIDS Research and Human Retroviruses, 2017, 33, 49-56.	1.1	33

#	Article	IF	Citations
109	Very Early ART and Persistent Inflammation in Treated HIV. Clinical Infectious Diseases, 2017, 64, 132-133.	5.8	13
110	High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. AIDS Research and Human Retroviruses, 2017, 33, 234-245.	1.1	3
111	Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. International Journal of STD and AIDS, 2017, 28, 800-807.	1.1	3
112	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infectious Diseases, 2017, 4, ofw278.	0.9	58
113	Immunologic Pathways That Predict Mortality in HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1270-1274.	4.0	33
114	Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathogens, 2017, 13, e1006202.	4.7	71
115	Prevalence and Risk Factors for Intimate Partner Violence in Women Living with HIV in Uganda. Open Forum Infectious Diseases, 2017, 4, S663-S663.	0.9	1
116	Cooking fuel and respiratory symptoms among people living with HIV in rural Uganda. ERJ Open Research, 2017, 3, 00094-2016.	2.6	11
117	Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathogens and Immunity, 2017, 2, 239.	3.1	2
118	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathogens and Immunity, 2017, 2, 310.	3.1	10
119	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
120	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS ONE, 2016, 11, e0166759.	2.5	10
121	Impact of early cART in the gut during acute HIV infection. JCI Insight, 2016, 1, .	5.0	56
122	Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. Aids, 2016, 30, 1781-1788.	2.2	2
123	HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 399-406.	2.1	24
124	D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 396-402.	2.1	18
125	HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. Aids, 2016, 30, 667-670.	2.2	23
126	Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. Aids, 2016, 30, 1807-1815.	2.2	13

#	Article	IF	Citations
127	Disease drivers of aging. Annals of the New York Academy of Sciences, 2016, 1386, 45-68.	3.8	97
128	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research and Human Retroviruses, 2016, 32, 791-800.	1.1	11
129	Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2016, 214, S44-S50.	4.0	195
130	Relationship Power and Sexual Violence Among HIV-Positive Women in Rural Uganda. AIDS and Behavior, 2016, 20, 2045-2053.	2.7	17
131	Immunologic profiles distinguish aviremic HIV-infected adults. Aids, 2016, 30, 1553-1562.	2.2	22
132	Reply to Barrett, et al. Clinical Infectious Diseases, 2016, 62, 1468-1469.	5.8	1
133	Soluble CD163 and Clinical Outcomes in Treated HIV Infection: Insights Into Mechanisms. Journal of Infectious Diseases, 2016, 214, 1132-1133.	4.0	10
134	Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 370-378.	4.0	69
135	Role of immune activation in progression to AIDS. Current Opinion in HIV and AIDS, 2016, 11, 131-137.	3.8	58
136	Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. Cell Host and Microbe, 2016, 19, 311-322.	11.0	330
137	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clinical Infectious Diseases, 2016, 62, 392-396.	5.8	114
138	Prospective Study of the Mental Health Consequences of Sexual Violence Among Women Living With HIV in Rural Uganda. Journal of Interpersonal Violence, 2016, 31, 1531-1553.	2.0	40
139	CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0005219.	3.0	50
140	Cooking Fuel Type and Respiratory Symptoms Among a Cohort of People Living With HIV in Rural Uganda. Chest, 2015, 148, 769A.	0.8	2
141	The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 296-303.	2.1	13
142	Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda. Journal of Hypertension, 2015, 33, 2039-2045.	0.5	51
143	Unhealthy Alcohol Use is Associated with Monocyte Activation Prior to Starting Antiretroviral Therapy. Alcoholism: Clinical and Experimental Research, 2015, 39, 2422-2426.	2.4	19
144	Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 386-392.	2.1	58

#	Article	lF	Citations
145	Safety of Fecal Microbial Transplantation During Treated HIV Infection. American Journal of Gastroenterology, 2015, 110, S578-S579.	0.4	1
146	Second European Round Table on the Future Management of HIV. Journal of Virus Eradication, 2015, 1 , 211-220.	0.5	3
147	Lymphoid Fibrosis Occurs in Long-Term Nonprogressors and Persists With Antiretroviral Therapy but May Be Reversible With Curative Interventions. Journal of Infectious Diseases, 2015, 211, 1068-1075.	4.0	49
148	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	4.0	138
149	The influence of partnership on contraceptive use among HIV-infected women accessing antiretroviral therapy in rural Uganda. Contraception, 2015, 92, 152-159.	1.5	18
150	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clinical Infectious Diseases, 2015, 61, 1189-1195.	5.8	36
151	Reply to Cannizzo et al. Journal of Infectious Diseases, 2015, 211, 1514-1515.	4.0	0
152	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
153	Gut epithelial barrier and systemic inflammation during chronic HIV infection. Aids, 2015, 29, 43-51.	2.2	156
154	Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. Aids, 2015, 29, 83-90.	2.2	63
155	Epigenetic mechanisms, T-cell activation, and <i>CCR5 < /i> genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4762-71.</i>	7.1	48
156	Declining Prevalence of Probable Depression Among Patients Presenting for Antiretroviral Therapy in Rural Uganda: The Role of Early Treatment Initiation. AIDS and Behavior, 2015, 19, 19-26.	2.7	11
157	The Factor Structure and Presentation of Depression Among HIV-Positive Adults in Uganda. AIDS and Behavior, 2015, 19, 27-33.	2.7	23
158	Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. Journal of Virus Eradication, 2015, 1, 211-20.	0.5	0
159	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
160	Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging. PLoS ONE, 2014, 9, e89444.	2.5	85
161	Comparison of Self-Reported Alcohol Consumption to Phosphatidylethanol Measurement among HIV-Infected Patients Initiating Antiretroviral Treatment in Southwestern Uganda. PLoS ONE, 2014, 9, e113152.	2.5	89
162	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1228-1238.	4.0	395

#	Article	IF	CITATIONS
163	HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy. Clinical Infectious Diseases, 2014, 58, 1599-1606.	5.8	39
164	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Nonâ€"AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2014, 210, 1248-1259.	4.0	464
165	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. PLoS Pathogens, 2014, 10, e1004345.	4.7	76
166	Empiric Deworming and CD4 Count Recovery in HIV-Infected Ugandans Initiating Antiretroviral Therapy. PLoS Neglected Tropical Diseases, 2014, 8, e3036.	3.0	11
167	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AlDS Morbidity and Mortality. PLoS Pathogens, 2014, 10, e1004078.	4.7	495
168	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 210, 383-391.	4.0	101
169	Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 133-141.	2.1	23
170	A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. Aids, 2014, 28, 439-442.	2.2	62
171	Reversal of the Kynurenine Pathway of Tryptophan Catabolism May Improve Depression in ART-Treated HIV-Infected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 456-462.	2.1	72
172	Point-of-Care C-Reactive Protein Testing to Facilitate Implementation of Isoniazid Preventive Therapy for People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 551-556.	2.1	25
173	HIV and aging. Current Opinion in HIV and AIDS, 2014, 9, 302-308.	3.8	42
174	CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda. Aids, 2014, 28, 1221-1226.	2.2	23
175	Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. Aids, 2014, 28, 979-987.	2.2	16
176	Depression During Pregnancy and the Postpartum Among HIV-Infected Women on Antiretroviral Therapy in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S179-S187.	2.1	53
177	Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. Aids, 2014, 28, 1749-1758.	2.2	101
178	A closer look at hepatitis C clearance in HIV controllers. Aids, 2014, 28, 1241-1242.	2.2	3
179	Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 153-160.	2.1	29
180	The Dynamic Relationship Between Social Support and HIV-Related Stigma in Rural Uganda. Annals of Behavioral Medicine, 2014, 48, 26-37.	2.9	104

#	Article	IF	CITATIONS
181	Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 2014, 505, 509-514.	27.8	931
182	Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda. AIDS Research and Human Retroviruses, 2014, 30, 896-906.	1.1	26
183	Persistent HIV-related Stigma in Rural Uganda during a Period of Increasing HIV Incidence. AIDS Research and Human Retroviruses, 2014, 30, A259-A259.	1.1	0
184	Subtype-Specific HIV-1 Adaptation to Host HLA. AIDS Research and Human Retroviruses, 2014, 30, A218-A218.	1.1	0
185	The CD8 ⁺ Memory Stem T Cell (T _{SCM}) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. Journal of Virology, 2014, 88, 13836-13844.	3.4	53
186	Antiretroviral therapy: stubborn limitations persist. Lancet, The, 2014, 384, 214-216.	13.7	2
187	Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda. AIDS and Behavior, 2014, 18, 1381-1389.	2.7	15
188	Low Proportions of CD28â^' CD8+ T cells Expressing CD57 Can Be Reversed by Early ART Initiation and Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 374-382.	4.0	53
189	Treatment as long-term prevention. Aids, 2014, 28, 267-271.	2.2	16
190	Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. Aids, 2014, 28, 115-120.	2.2	137
191	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e116306.	2.5	56
192	Residual Immune Dysregulation Syndrome in Treated HIV infection. Advances in Immunology, 2013, 119, 51-83.	2.2	295
193	Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. Science Translational Medicine, 2013, 5, 193ra91.	12.4	578
194	Internalized Stigma, Social Distance, and Disclosure of HIV Seropositivity in Rural Uganda. Annals of Behavioral Medicine, 2013, 46, 285-294.	2.9	129
195	The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4987-96.	7.1	260
196	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	2.0	68
197	No Association Found Between Traditional Healer Use and Delayed Antiretroviral Initiation in Rural Uganda. AIDS and Behavior, 2013, 17, 260-265.	2.7	12
198	Evidence for the Reliability and Validity of the Internalized AIDS-Related Stigma Scale in Rural Uganda. AIDS and Behavior, 2013, 17, 427-433.	2.7	59

#	Article	IF	CITATIONS
199	Short Communication: HIV+ Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation. AIDS Research and Human Retroviruses, 2013, 29, 172-177.	1.1	13
200	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Journal of Infectious Diseases, 2013, 208, 1202-1211.	4.0	285
201	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2013, 57, 756-764.	5.8	107
202	How Does Antiretroviral Treatment Attenuate the Stigma of HIV? Evidence from a Cohort Study in Rural Uganda. AIDS and Behavior, 2013, 17, 2725-2731.	2.7	75
203	Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. Aids, 2013, 27, 2691-2696.	2.2	9
204	Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. Aids, 2013, 27, 1735-1742.	2.2	52
205	Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment. HIV Clinical Trials, 2013, 14, 61-67.	2.0	21
206	GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. Aids, 2013, 27, 1503-1508.	2.2	83
207	Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 254-260.	2.1	18
208	Realtime adherence monitoring of antiretroviral therapy among hiv-infected adults and children in rural uganda. Aids, 2013, 27, 2166-2168.	2.2	62
209	Dissemination of Research Findings to Research Participants Living with HIV in Rural Uganda: Challenges and Rewards. PLoS Medicine, 2013, 10, e1001397.	8.4	23
210	Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. PLoS Pathogens, 2013, 9, e1003691.	4.7	94
211	Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells. Journal of Infectious Diseases, 2013, 208, 50-56.	4.0	227
212	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	4.7	524
213	AIDS Alters the Commensal Plasma Virome. Journal of Virology, 2013, 87, 10912-10915.	3.4	89
214	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 2013, 121, 4635-4646.	1.4	117
215	Genetic interplay between <i>HLA-C</i> and <i>MIR148A</i> in HIV control and Crohn disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20705-20710.	7.1	109
216	A simple LC–MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis, 2013, 5, 1397-1407.	1.5	66

#	Article	IF	Citations
217	Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000–2010. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 216-220.	2.1	1
218	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood, 2013, 121, 1124-1135.	1.4	347
219	Response: maraviroc intensification and microbial translocation. Blood, 2013, 122, 2283-2284.	1.4	5
220	Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. Aids, 2013, 27, 2255-2260.	2.2	44
221	The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. Aids, 2013, 27, 2101-2110.	2.2	18
222	HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods. Aids, 2013, 27, S105-S112.	2.2	23
223	Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 317-321.	2.1	43
224	CD8+ T-Cell Activation in HIV-1–Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 101-104.	2.1	29
225	Disinhibition in Risky Sexual Behavior in Men, but Not Women, during Four Years of Antiretroviral Therapy in Rural, Southwestern Uganda. PLoS ONE, 2013, 8, e69634.	2.5	16
226	Higher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection. PLoS ONE, 2013, 8, e84091.	2.5	9
227	Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda. PLoS ONE, 2013, 8, e63411.	2.5	51
228	CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapy–Naive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. Journal of Infectious Diseases, 2012, 205, 1730-1738.	4.0	31
229	Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. Journal of Infectious Diseases, 2012, 205, 1788-1796.	4.0	100
230	Carotid Intimaâ€Media Thickness Progression in HIVâ€Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. Journal of the American Heart Association, 2012, 1, .	3.7	87
231	Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. Journal of Infectious Diseases, 2012, 205, S375-S382.	4.0	228
232	Changes in Food Insecurity, Nutritional Status, and Physical Health Status After Antiretroviral Therapy Initiation in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 179-186.	2.1	36
233	Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. Aids, 2012, 26, 67-75.	2.2	146
234	A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. Aids, 2012, 26, 805-814.	2.2	83

#	Article	IF	Citations
235	Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood, 2012, 119, 745-755.	1.4	38
236	Leaky gut, clotting, and vasculopathy in SIV. Blood, 2012, 120, 1350-1351.	1.4	1
237	HIV and Inflammation: Mechanisms and Consequences. Current HIV/AIDS Reports, 2012, 9, 139-147.	3.1	333
238	Sexual Relationship Power and Malnutrition Among HIV-Positive Women in Rural Uganda. AIDS and Behavior, 2012, 16, 1542-1548.	2.7	14
239	Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Social Science and Medicine, 2012, 74, 2012-2019.	3.8	253
240	Optimizing Network Connectivity for Mobile Health Technologies in sub-Saharan Africa. PLoS ONE, 2012, 7, e45643.	2.5	25
241	Sexual Relationship Power and Depression among HIV-Infected Women in Rural Uganda. PLoS ONE, 2012, 7, e49821.	2.5	50
242	Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection. PLoS ONE, 2012, 7, e50486.	2.5	14
243	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood, 2011, 117, 5142-5151.	1.4	140
244	T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis, 2011, 217, 207-213.	0.8	117
245	A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. PLoS ONE, 2011, 6, e15924.	2.5	122
246	Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids, 2011, 25, 2123-2131.	2.2	195
247	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. Aids, 2011, 25, 1813-1822.	2.2	140
248	Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature, 2011, 472, 495-498.	27.8	328
249	Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. Journal of the International AIDS Society, 2011, 14, 46.	3.0	43
250	HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers. Clinical Infectious Diseases, 2011, 52, 681-687.	5.8	33
251	Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. Journal of Infectious Diseases, 2011, 203, 1474-1483.	4.0	308
252	A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. Journal of Infectious Diseases, 2011, 203, 960-968.	4.0	176

#	Article	IF	Citations
253	Regional Anthropometry Changes in Antiretroviral-NaÃ-ve Persons Initiating a Zidovudine-Containing Regimen in Mbarara, Uganda. AIDS Research and Human Retroviruses, 2011, 27, 785-791.	1.1	13
254	Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers. Journal of Virology, 2011, 85, 11422-11434.	3.4	98
255	Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons. Clinical Infectious Diseases, 2011, 52, 941-944.	5.8	44
256	T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women. Journal of Infectious Diseases, 2011, 203, 452-463.	4.0	281
257	Th17, gut, and HIV: therapeutic implications. Current Opinion in HIV and AIDS, 2010, 5, 189-193.	3.8	62
258	Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. Aids, 2010, 24, 2535-2539.	2.2	61
259	Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood, 2010, 115, e20-e32.	1.4	36
260	Real-Time Adherence Monitoring for HIV Antiretroviral Therapy. AIDS and Behavior, 2010, 14, 1340-1346.	2.7	192
261	Potential inflammatory consequences in HIV controllers. Retrovirology, 2010, 7, .	2.0	0
262	Cytomegalovirus-Specific T Cells Persist at Very High Levels during Long-Term Antiretroviral Treatment of HIV Disease. PLoS ONE, 2010, 5, e8886.	2.5	176
263	Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T _H 17 to Regulatory T Cells in HIV Disease. Science Translational Medicine, 2010, 2, 32ra36.	12.4	454
264	HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4 ⁺ T-Cell Responses. Journal of Virology, 2010, 84, 11020-11029.	3.4	102
265	Immunodominant HIV-Specific CD8 ⁺ T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. Journal of Virology, 2010, 84, 10354-10365.	3.4	61
266	Impact of HIV Infection on Diastolic Function and Left Ventricular Mass. Circulation: Heart Failure, 2010, 3, 132-139.	3.9	163
267	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. Aids, 2010, 24, 1001-1005.	2.2	25
268	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	12.6	1,054
269	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviralâ€Treated HIV Infection. Journal of Infectious Diseases, 2009, 199, 1177-1185.	4.0	527
270	Incomplete Peripheral CD4 ⁺ Cell Count Restoration in HIVâ€Infected Patients Receiving Longâ€Term Antiretroviral Treatment. Clinical Infectious Diseases, 2009, 48, 787-794.	5.8	329

#	Article	IF	Citations
271	Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. Journal of Virology, 2009, 83, 329-335.	3.4	191
272	HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. Aids, 2009, 23, 2143-2149.	2.2	99
273	Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. Aids, 2009, 23, 1059-1067.	2.2	324
274	Natural Control of HIVâ€1 Replication and Longâ€Term Nonprogression: Overlapping but Distinct Phenotypes. Journal of Infectious Diseases, 2009, 200, 1636-1638.	4.0	26
275	Infection With Different HIV Subtypes Is Associated With CD4 Activation-Associated Dysfunction and Apoptosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 548-552.	2.1	22
276	Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. Aids, 2009, 23, 2021-2027.	2.2	137
277	Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood, 2009, 113, 3978-3989.	1.4	198
278	Human Herpesvirus Replication and Abnormal CD8+ T Cell Activation and Low CD4+ T Cell Counts in Antiretroviral-Suppressed HIV-Infected Patients. PLoS ONE, 2009, 4, e5277.	2.5	18
279	Relationship between T Cell Activation and CD4 ⁺ T Cell Count in HIVâ€6eropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. Journal of Infectious Diseases, 2008, 197, 126-133.	4.0	579
280	Host genetic determinants of HIV pathogenesis: an immunologic perspective. Current Opinion in HIV and AIDS, 2008, 3, 342-348.	3.8	13
281	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 544-552.	2.1	52
282	Interruption of Enfuvirtide in HIVâ€1–Infected Adults with Incomplete Viral Suppression on an Enfuvirtideâ€Based Regimen. Journal of Infectious Diseases, 2007, 195, 387-391.	4.0	41
283	Role of immune activation in HIV pathogenesis. Current HIV/AIDS Reports, 2007, 4, 42-47.	3.1	61
284	Immuneâ€Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases?. Journal of Infectious Diseases, 2006, 194, 1632-1634.	4.0	16
285	Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses. Journal of Virology, 2006, 80, 6155-6164.	3.4	127
286	The independent effect of drug resistance on T cell activation in HIV infection. Aids, 2006, 20, 691-699.	2.2	35
287	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids, 2006, 20, 2275-2283.	2.2	239
288	Prevalence of CXCR4 Tropism among Antiretroviralâ€Treated HIVâ€1–Infected Patients with Detectable Viremia. Journal of Infectious Diseases, 2006, 194, 926-930.	4.0	137

#	Article	IF	CITATIONS
289	Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Clinical Infectious Diseases, 2006, 43, 1329-1336.	5.8	87
290	A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide. Antiviral Therapy, 2006, 11, 315-319.	1.0	9
291	Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids, 2004, 18, 981-989.	2.2	101
292	Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood, 2004, 104, 942-947.	1.4	688
293	T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 1534-1543.	4.0	786
294	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. Aids, 2003, 17, 1907-1915.	2.2	229
295	Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. Frontiers in Virology, $0,2,.$	1.4	0
296	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. Biomarkers in Medicine, 0 , , .	1.4	1